FDA Approves Eli Lilly's Olumiant for Pediatric Alopecia Areata Treatment
Eli Lilly secures FDA approval for Olumiant in pediatric alopecia areata, marking a key label expansion following successful Phase 3 clinical trial…
Eli Lilly secures FDA approval for Olumiant in pediatric alopecia areata, marking a key label expansion following successful Phase 3 clinical trial…
Scholar Rock rallies 9% as FDA approval of its muscle-targeted therapy for spinal muscular atrophy prompts a wave of analyst price target…
Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…
Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…
UniQure stock pops following FDA’s reversal allowing Huntington’s disease therapy AMT-130 to move toward US approval filing.
FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.
FDA gridlock clouds drug approval timelines, pressuring healthcare stocks and ETFs like XLV and IBB.